sorafenib has been researched along with Benign Cerebellar Neoplasms in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Craveiro, RB; Dilloo, D; Jordans, S; Moritz, T; Pietsch, T; Schoen, LF; Troeger, A | 1 |
| Craveiro, RB; Dilloo, D; Ehrhardt, M; Holst, MI; Pietsch, T | 1 |
| Buettner, R; Chen, MY; Hedvat, M; Jove, R; Kirschbaum, M; Kowolik, CM; Liang, W; Mepani, N; Mirosevich, J; Nam, S; Tye, G; Van Meter, TE; Yang, F | 1 |
| Buettner, R; Chang, S; Hedvat, M; Jove, R; Jove, V; Liu, L; Scuto, A; Tian, Y; Van Meter, T; Wen, W; Yang, F; Yen, Y; Yip, ML | 1 |
4 other study(ies) available for sorafenib and Benign Cerebellar Neoplasms
| Article | Year |
|---|---|
The PI3K inhibitor pictilisib and the multikinase inhibitors pazopanib and sorafenib have an impact on Rac1 level and migration of medulloblastoma in vitro.
Topics: Cell Line, Tumor; Cell Movement; Cerebellar Neoplasms; Humans; Medulloblastoma; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; rac1 GTP-Binding Protein; Sorafenib | 2022 |
In comparative analysis of multi-kinase inhibitors for targeted medulloblastoma therapy pazopanib exhibits promising in vitro and in vivo efficacy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cerebellar Neoplasms; Dose-Response Relationship, Drug; Female; Humans; Indazoles; Male; Medulloblastoma; Mice; Mice, Inbred NOD; Mice, SCID; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Sorafenib; Sulfonamides; Xenograft Model Antitumor Assays | 2014 |
Sorafenib inhibits signal transducer and activator of transcription 3 signaling associated with growth arrest and apoptosis of medulloblastomas.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cerebellar Neoplasms; Cyclin D; Cyclins; Down-Regulation; Humans; Medulloblastoma; Mice; Mice, Nude; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-bcl-2; Pyridines; Signal Transduction; Sorafenib; STAT3 Transcription Factor; Transfection | 2008 |
Bortezomib induces apoptosis and growth suppression in human medulloblastoma cells, associated with inhibition of AKT and NF-ĸB signaling, and synergizes with an ERK inhibitor.
Topics: Amino Acid Chloromethyl Ketones; Antineoplastic Agents; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; bcl-Associated Death Protein; Boronic Acids; Bortezomib; Caspase 3; Caspase 9; Cerebellar Neoplasms; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Cytochromes c; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Humans; Medulloblastoma; NF-kappa B; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazines; Sorafenib; Tumor Cells, Cultured | 2012 |